{"database":"panorama","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Jenny Hallqvist"],"species":["Homo Sapiens"],"full_dataset_link":["https://panoramaweb.org/AD_Urine_Proteomics.url"],"submitter_email":["j.hallqvist@ucl.ac.uk"],"submitter_affiliation":["Great Ormond Street Institute of Child Health, University College London"],"sample_protocol":[""],"repository":["PanoramaPublic"],"data_protocol":[""],"pubmed_abstract":["As disease-modifying therapies are now available for Alzheimer's disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput screening tool for diagnosing AD. We collected urine from a discovery cohort (n = 11) of well-characterised individuals with AD (n = 6) and their asymptomatic, CSF biomarker-negative study partners (n = 5) and used untargeted proteomics for biomarker discovery. Protein biomarkers identified were taken forward to develop a high-throughput, multiplexed and targeted proteomic assay which was tested on an independent cohort (n = 21). The panel of proteins identified are known to be involved in AD pathogenesis. In comparing AD and controls, a panel of proteins including MIEN1, TNFB, VCAM1, REG1B and ABCA7 had a classification accuracy of 86%. These proteins have been previously implicated in AD pathogenesis. This suggests that urine-targeted mass spectrometry has potential utility as a diagnostic screening tool in AD."],"pubmed_title":["A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer's Disease Diagnosis Using Targeted Proteomics and Machine Learning."],"pubmed_authors":["Hällqvist Jenny J, Pinto Rui C RC, Heywood Wendy E WE, Cordey Jonjo J, Foulkes Alexander J M AJM, Slattery Catherine F CF, Leckey Claire A CA, Murphy Eimear C EC, Zetterberg Henrik H, Schott Jonathan M JM, Mills Kevin K, Paterson Ross W RW"],"additional_accession":[]},"is_claimable":false,"name":"A multiplexed urinary biomarker panel has potential for Alzheimer’s Disease Diagnosis using targeted proteomics and machine learning","description":"As disease-modifying therapies are now available for Alzheimer’s disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test  as a high-throughput screening tool for diagnosing AD. We collected urine from a discovery cohort (n=11) of well characterised individuals with AD (n=6) and their asymptomatic, CSF biomarker negative study partners (n=5) and used untargeted proteomics for biomarker discovery. Protein biomarkers identified were taken forward to develop a high-throughput, multiplexed and targeted proteomic assay which was tested on an independent cohort (n=21). The panel of proteins identified are known to be involved in AD pathogenesis. In comparing AD and controls, a panel of proteins including MIEN1, TNFB, VCAM1, REG1B and ABCA7 had a classification accuracy of 86%. These proteins have been previously implicated in AD pathogenesis. This suggests that urine targeted mass spectrometry has potential utility as a diagnostic screening tool in AD.","dates":{"publication":"Mon May 04 00:00:00 BST 2026"},"accession":"PXD044751","cross_references":{"TAXONOMY":["9606"],"pubmed":["37762058"]}}